PCMC
CPRX

Planning Capital Management Corporation’s Catalyst Pharmaceutical CPRX Stock Holding History

Planning Capital Management Corporation’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$60 Buy
3
+2
+200% +$37 ﹤0.01% 734
2024
Q2 		$16 Buy
+1
New +$16 ﹤0.01% 711

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Planning Capital Management Corporation's CPRX Position: Q3 2024 in Review

Planning Capital Management Corporation increased its Catalyst Pharmaceutical (CPRX) stake by 200% in Q3 2024, buying an estimated $37 and bringing the position to 3 shares worth $60. The position accounts for ﹤0.01% of the portfolio, ranked #734.

Planning Capital Management Corporation first reported a position in CPRX in Q2 2024 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Planning Capital Management Corporation held 3 shares of Catalyst Pharmaceutical worth $60 as of Q3 2024.
  • Planning Capital Management Corporation bought 2 Catalyst Pharmaceutical shares in Q3 2024, an estimated $37.
  • Catalyst Pharmaceutical made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #734 holding.
  • Planning Capital Management Corporation first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.